

Junji Uchino

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7492806/junji-uchino-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

85
papers

876
citations

15
h-index

26
g-index

92
ext. papers

1,296
ext. citations

4.3
avg, IF

4.09
L-index

#	Paper	IF	Citations
85	HER3 activation contributes toward the emergence of ALK inhibitor-tolerant cells in ALK-rearranged lung cancer with mesenchymal features.. <i>Npj Precision Oncology</i> , 2022 , 6, 5	9.8	0
84	Prognostic Nutritional Index and Lung Immune Prognostic Index as Prognostic Predictors for Combination Therapies of Immune Checkpoint Inhibitors and Cytotoxic Anticancer Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer.. <i>Diagnostics</i> , 2022 , 12,	3.8	3
83	Neoadjuvant immunotherapy or chemoimmunotherapy in non-small cell lung cancer: a systematic review and meta-analysis.. <i>Translational Lung Cancer Research</i> , 2022 , 11, 277-294	4.4	1
82	A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in patients with cancer cachexia and low body mass index.. <i>Cancer</i> , 2022 ,	6.4	2
81	Impact of maintenance therapy following induction immunochemotherapy for untreated advanced non-small cell lung cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021 , 1	4.9	0
80	TTF-1 and c-MYC-defined Phenotypes of Large Cell Neuroendocrine Carcinoma and Delta-like Protein 3 Expression for Treatment Selection. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2021 , 29, 313-320	1.9	2
79	Immune-Related Adverse Events Are Associated With Clinical Benefit in Patients With Non-Small-Cell Lung Cancer Treated With Immunotherapy Plus Chemotherapy: A Retrospective Study. <i>Frontiers in Oncology</i> , 2021 , 11, 630136	5.3	3
78	Anlotinib combined with gefitinib can significantly improve the proliferation of epidermal growth factor receptor-mutant advanced non-small cell lung cancer and. <i>Translational Lung Cancer Research</i> , 2021 , 10, 1873-1888	4.4	6
77	The Impact of VEGF Inhibition on Clinical Outcomes in Patients With Advanced Non-Small Cell Lung Cancer Treated With Immunotherapy: A Retrospective Cohort Study. <i>Frontiers in Oncology</i> , 2021 , 11, 663612	5.3	4
76	Impact of cancer cachexia on the therapeutic outcome of combined chemoimmunotherapy in patients with non-small cell lung cancer: a retrospective study. <i>OncImmunology</i> , 2021 , 10, 1950411	7.2	5
75	Late-onset Pleural and Pericardial Effusion as Immune-related Adverse Events after 94 Cycles of Nivolumab. <i>Internal Medicine</i> , 2021 , 60, 3585-3588	1.1	1
74	Prognostic factors in older patients with wild-type epidermal growth factor receptor advanced non-small cell lung cancer: a multicenter retrospective study. <i>Translational Lung Cancer Research</i> , 2021 , 10, 193-201	4.4	0
73	Impact of tumor programmed death ligand-1 expression on osimertinib efficacy in untreated -mutated advanced non-small cell lung cancer: a prospective observational study. <i>Translational Lung Cancer Research</i> , 2021 , 10, 3582-3593	4.4	1
72	Early discontinuation of induction therapy in chemoimmunotherapy as an effective alternative to the standard regimen in patients with non-small cell lung cancer: a retrospective study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021 , 1	4.9	0
71	Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021 , 10, 3713-3736	4.4	0
70	Clinical impact of pembrolizumab combined with chemotherapy in elderly patients with advanced non-small-cell lung cancer. <i>Lung Cancer</i> , 2021 , 161, 26-33	5.9	6
69	Inhibition of c-Jun N-terminal kinase signaling increased apoptosis and prevented the emergence of ALK-TKI-tolerant cells in ALK-rearranged non-small cell lung cancer. <i>Cancer Letters</i> , 2021 , 522, 119-128	8.9	3

68	Immune Checkpoint Inhibitors for Lung Cancer Treatment: A Review. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	45
67	Randomized Phase II Study of First-Line Biweekly Gemcitabine and Carboplatin Versus Biweekly Gemcitabine and Carboplatin plus Maintenance Gemcitabine in Elderly Patients with Untreated Non-Small Cell Lung Cancer: LOGIK0801. <i>Oncologist</i> , 2020 , 25, e1146-e1157	5.7	
66	Respiratory complications of Stevens-Johnson syndrome (SJS): 3 cases of SJS-induced obstructive bronchiolitis. <i>Allergology International</i> , 2020 , 69, 465-467	4.4	1
65	Final Results from a Phase II Trial of Osimertinib for Elderly Patients with Epidermal Growth Factor Receptor t790m-Positive Non-Small Cell Lung Cancer That Progressed during Previous Treatment. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	3
64	Rationale and design of a phase II trial of durvalumab treatment in patients with NSCLC ineligible for stage III chemoradiotherapy following radiation monotherapy (SPIRAL-RT study). <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920927841	5.4	6
63	Efficacy and safety of immune checkpoint inhibitor monotherapy in pretreated elderly patients with non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2020 , 85, 761-771	3.5	19
62	Endocrinopathies Associated with Immune Checkpoint Inhibitor Cancer Treatment: A Review. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	5
61	ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in -Mutated Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 2244-2256	12.9	36
60	The Quality of Life of Patients with Suspected Lung Cancer before and after Bronchoscopy and the Effect of Mirtazapine on the Depressive Status. <i>Internal Medicine</i> , 2020 , 59, 1605-1610	1.1	1
59	Education Program for Male Patients with Chronic Obstructive Pulmonary Disease to Change Dietary Behavior. <i>Kobe Journal of Medical Sciences</i> , 2020 , 66, E82-E89	0.6	
58	Safety and tolerability of PD-1/PD-L1 inhibitors in elderly and frail patients with advanced malignancies. <i>Oncology Letters</i> , 2020 , 20, 14	2.6	5
57	Phase II Study on Biweekly Combination Therapy of Gemcitabine plus Carboplatin for the Treatment of Elderly Patients with Advanced Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2020 , 25, 208-e417	5.7	2
56	Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged ≥ 75 years) with non-small cell lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020 , 146, 457-466	4.9	10
55	Significance of inflammatory indexes in atezolizumab monotherapy outcomes in previously treated non-small-cell lung cancer patients. <i>Scientific Reports</i> , 2020 , 10, 17495	4.9	6
54	Association of immune checkpoint inhibitors with respiratory infections: A review. <i>Cancer Treatment Reviews</i> , 2020 , 90, 102109	14.4	1
53	Serum immune modulators during the first cycle of anti-PD-1 antibody therapy in non-small cell lung cancer: Perforin as a biomarker. <i>Thoracic Cancer</i> , 2020 , 11, 3223-3233	3.2	0
52	Impact of preexisting antinuclear antibodies on combined immunotherapy and chemotherapy in advanced non-small cell lung cancer patients. <i>Medical Oncology</i> , 2020 , 37, 111	3.7	2
51	Efficacy and safety of S-1 monotherapy in previously treated elderly patients (aged ≥ 5 years) with non-small cell lung cancer: A retrospective analysis. <i>Thoracic Cancer</i> , 2020 , 11, 2867-2876	3.2	2

50	Comparing three different anti-PD-L1 antibodies for immunohistochemical evaluation of small cell lung cancer. <i>Lung Cancer</i> , 2019 , 137, 108-112	5.9	9
49	Retrospective analysis of docetaxel in combination with ramucirumab for previously treated non-small cell lung cancer patients. <i>Translational Lung Cancer Research</i> , 2019 , 8, 450-460	4.4	8
48	Prognostic impact of pleural effusion in EGFR-mutant non-small cell lung cancer patients without brain metastasis. <i>Thoracic Cancer</i> , 2019 , 10, 557-563	3.2	3
47	Impact of bowel movement condition on immune checkpoint inhibitor efficacy in patients with advanced non-small cell lung cancer. <i>Thoracic Cancer</i> , 2019 , 10, 526-532	3.2	7
46	Osimertinib in Elderly Patients with Epidermal Growth Factor Receptor T790M-Positive Non-Small-Cell Lung Cancer Who Progressed During Prior Treatment: A Phase II Trial. <i>Oncologist</i> , 2019 , 24, 593-e170	5.7	8
45	Phase II Study of S-1 and Paclitaxel Combination Therapy in Patients with Previously Treated Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2019 , 24, 1033-e617	5.7	3
44	Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients with EGFR-T790M Mutation. <i>Cancers</i> , 2019 , 11,	6.6	8
43	Nicotine Induces Resistance to Erlotinib Therapy in Non-Small-Cell Lung Cancer Cells Treated with Serum from Human Patients. <i>Cancers</i> , 2019 , 11,	6.6	7
42	Safety and Usefulness of Cryobiopsy and Stamp Cytology for the Diagnosis of Peripheral Pulmonary Lesions. <i>Cancers</i> , 2019 , 11,	6.6	15
41	Tumor Neovascularization and Developments in Therapeutics. <i>Cancers</i> , 2019 , 11,	6.6	46
40	Rationale and Design of a Phase II Trial of Osimertinib Combined With Bevacizumab in Patients With Untreated Epidermal Growth Factor Receptor-mutated Non-small-cell Lung Cancer and Malignant Pleural and/or Pericardial Effusion (SPIRAL II Study). <i>Clinical Lung Cancer</i> , 2019 , 20, e402-e406	4.9	5
39	Association of Sarcopenia with and Efficacy of Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	49
38	Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR-mutated non-small cell lung cancer. <i>Cancer Medicine</i> , 2019 , 8, 1521-1529	4.8	41
37	Phase I study of S-1 plus paclitaxel combination therapy as a first-line treatment in elderly patients with advanced non-small cell lung cancer. <i>Investigational New Drugs</i> , 2019 , 37, 291-296	4.3	4
36	Clinical features of immune-related thyroid dysfunction and its association with outcomes in patients with advanced malignancies treated by PD-1 blockade. <i>Oncology Letters</i> , 2019 , 18, 2140-2147	2.6	21
35	Carcinoembryonic antigen and CYFRA 21-1 responses as prognostic factors in advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2019 , 8, 227-234	4.4	10
34	Randomized Phase II Study of Weekly Paclitaxel plus Carboplatin Versus Biweekly Paclitaxel plus Carboplatin for Patients with Previously Untreated Advanced Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2019 , 24, 1420-e1010	5.7	3
33	Rationale and design of a phase II study to evaluate prophylactic treatment of dacomitinib-induced dermatologic adverse events in epidermal growth factor receptor-mutated advanced non-small cell lung cancer (SPIRAL-Daco study). <i>Translational Lung Cancer Research</i> , 2019 , 8, 519-523	4.4	

32	The Impact of Immune-related Adverse Events on the Effect of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer. <i>Japanese Journal of Lung Cancer</i> , 2019 , 59, 128-136	0.1	2
31	Retrospective Efficacy Analysis of Immune Checkpoint Inhibitor Rechallenge in Patients with Non-Small Cell Lung Cancer. <i>Journal of Clinical Medicine</i> , 2019 , 9,	5.1	26
30	The role of the gut microbiome on the efficacy of immune checkpoint inhibitors in Japanese responder patients with advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2019 , 8, 847-853	4.4	24
29	Rationale and design of a phase II trial of osimertinib as first-line treatment for elderly patients with epidermal growth factor receptor mutation-positive advanced non-small cell lung cancer (SPIRAL-0 study). <i>Translational Lung Cancer Research</i> , 2019 , 8, 1086-1090	4.4	3
28	A Phase II Study of S-1 and Paclitaxel Combination Therapy as a First-Line Treatment in Elderly Patients with Advanced Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2019 , 24, 459-e131	5.7	2
27	AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells. <i>Nature Communications</i> , 2019 , 10, 259	17.4	116
26	Nab-paclitaxel maintenance therapy following carboplatin + nab-paclitaxel combination therapy in chemotherapy naïve patients with advanced non-small cell lung cancer: multicenter, open-label, single-arm phase II trial. <i>Investigational New Drugs</i> , 2018 , 36, 903-910	4.3	5
25	Treatment rationale and design of the SPIRAL study: A phase II trial of osimertinib in elderly epidermal growth factor receptor T790M-positive nonsmall-cell lung cancer patients who progressed during prior EGFR-TKI treatment. <i>Medicine (United States)</i> , 2018 , 97, e11081	1.8	5
24	Treatment rationale and design of the RAMNITA study: A phase II study of the efficacy of docetaxel + ramucirumab for non-small cell lung cancer with brain metastasis. <i>Medicine (United States)</i> , 2018 , 97, e11084	1.8	5
23	Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: Results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04). <i>Cancer</i> , 2018 , 124, 606-616	6.4	75
22	The impact of the tumor shrinkage by initial EGFR inhibitors according to the detection of EGFR-T790M mutation in patients with non-small cell lung cancer harboring EGFR mutations. <i>BMC Cancer</i> , 2018 , 18, 1241	4.8	1
21	Successful sequential treatment of refractory tumors caused by small cell carcinoma transformation and EGFR-T790M mutation diagnosed by repeated genetic testing in a patient with lung adenocarcinoma harboring epidermal growth factor receptor mutations: A case report. <i>Journal of Clinical Medicine</i> , 2018 , 7, 261-268	1.2	5
20	An observational study of the epidermal growth factor receptor-tyrosine kinase inhibitor resistance mechanism in epidermal growth factor receptor gene mutation-positive non-small cell lung cancer. <i>Medicine (United States)</i> , 2018 , 97, e12660	1.8	
19	A phase II study of afatinib treatment for elderly patients with previously untreated advanced non-small-cell lung cancer harboring EGFR mutations. <i>Lung Cancer</i> , 2018 , 126, 41-47	5.9	21
18	Advanced Non-Small-Cell Lung Cancer in Elderly Patients: Patient Features and Therapeutic Management. <i>BioMed Research International</i> , 2018 , 2018, 8202971	3	13
17	Vascular endothelial growth factor promoter-based conditionally replicative adenoviruses effectively suppress growth of malignant pleural mesothelioma. <i>Cancer Science</i> , 2017 , 108, 116-123	6.9	6
16	Low-dose Epidermal Growth Factor Receptor (EGFR)- Tyrosine Kinase Inhibition of EGFR Mutation-positive Lung Cancer: Therapeutic Benefits and Associations Between Dosage, Efficacy and Body Surface Area. <i>Asian Pacific Journal of Cancer Prevention</i> , 2016 , 17, 785-9	1.7	5
15	Chronic infection-induced chronic bronchitis and emphysematous changes in CCSP-deficient mice. <i>International Journal of COPD</i> , 2016 , 11, 2321-2327	3	8

14	Critical role of tumor necrosis factor receptor 1 in the pathogenesis of pulmonary emphysema in mice. <i>International Journal of COPD</i> , 2016 , 11, 1705-12	3	12
13	Adenoid Cystic Carcinoma of the Lung with an EGFR Mutation. <i>Internal Medicine</i> , 2016 , 55, 1621-4	1.1	6
12	Pulmonary MALT lymphoma demonstrating a crazy-paving appearance on imaging. <i>Internal Medicine</i> , 2015 , 54, 2705-6	1.1	1
11	Species D human adenovirus type 9 exhibits better virus-spread ability for antitumor efficacy among alternative serotypes. <i>PLoS ONE</i> , 2014 , 9, e87342	3.7	7
10	Elevation of serum C-reactive protein predicts failure of the initial antimicrobial treatment for febrile neutropenia with lung cancer. <i>Journal of Infection and Chemotherapy</i> , 2013 , 19, 202-7	2.2	1
9	Identifying risk factors for refractory febrile neutropenia in patients with lung cancer. <i>Journal of Infection and Chemotherapy</i> , 2012 , 18, 53-8	2.2	5
8	The clinical efficacy and safety of micafungin-itraconazole combination therapy in patients with pulmonary aspergilloma. <i>Journal of Infection and Chemotherapy</i> , 2012 , 18, 668-74	2.2	15
7	First reported case of hemoglobin lancing in Asia detected by false low oxygen saturation on pulse oximetry. <i>International Journal of Hematology</i> , 2012 , 95, 731-2	2.3	5
6	The clinical efficacy and safety of a fluoroquinolone-containing regimen for pulmonary MAC disease. <i>Journal of Infection and Chemotherapy</i> , 2012 , 18, 146-51	2.2	19
5	Efficacy of aprepitant in patients with advanced or recurrent lung cancer receiving moderately emetogenic chemotherapy. <i>Asian Pacific Journal of Cancer Prevention</i> , 2012 , 13, 4187-90	1.7	9
4	A new cancer cell detection method using an infectivity-enhanced adenoviral vector. <i>Asian Pacific Journal of Cancer Prevention</i> , 2012 , 13, 5551-6	1.7	
3	Combination with low-dose gemcitabine and hTERT-promoter-dependent conditionally replicative adenovirus enhances cytotoxicity through their crosstalk mechanisms in pancreatic cancer. <i>Cancer Letters</i> , 2010 , 294, 178-86	9.9	21
2	Infectivity enhanced, hTERT promoter-based conditionally replicative adenoviruses are useful for SCLC treatment. <i>Cancer Gene Therapy</i> , 2005 , 12, 737-48	5.4	21
1	Overexpression of I.KAPPA.B.ALPHA. Suppresses Lung Cancer Growth Through Reduced VEGF Production. <i>Japanese Journal of Lung Cancer</i> , 2005 , 45, 13-18	0.1	